Munich — Inter­na­tio­nal law firm Clif­ford Chance has advi­sed venture capi­tal inves­tor TVM Capi­tal Life Science on the signi­fi­cantly over­sub­scri­bed closing of its TVM Life Science Inno­va­tion II fund. At $478 million, the fund repres­ents the company’s largest fund to date.

TVM, a leading life science venture capi­tal firm in North America and Europe, provi­des venture capi­tal to inter­na­tio­nal biophar­maceu­ti­cal, medi­cal device and diagno­stic compa­nies in North America and Europe. The Company invests in compa­nies that offer a visi­ble and attrac­tive exit stra­tegy from the outset, with the aim of maxi­mi­zing returns and gene­ra­ting signi­fi­cant liqui­dity for inves­tors at an early stage.

With support from top-tier dome­stic and inter­na­tio­nal inves­tors, inclu­ding Eli Lilly, other stra­te­gic inves­tors, pension funds, endow­ments, funds of funds, asset mana­gers and leading U.S. banks, as well as family offices from North and South America, Europe and South Korea, TVM closed its fund at a total of $478 million.

TVM was foun­ded in 1983 and is inter­na­tio­nally posi­tio­ned with offices in Luxem­bourg and Canada as well as consul­ting offices in Germany and other locations.

Advi­sor TVM: Clif­ford Chance
The inter­na­tio­nal Clif­ford Chance team for TVM was led by part­ner Sonya Pauls (Corporate/Private Equity, Munich).

About Clif­ford Chance
Clif­ford Chance, one of the world’s leading law firms, is present for its clients with around 3,400 legal advi­sors in all major busi­ness centers around the world.
In Germany, Clif­ford Chance is repre­sen­ted by around 300 lawy­ers, audi­tors, tax advi­sors and soli­ci­tors in Düssel­dorf, Frank­furt am Main and Munich.